Australia markets open in 1 hour 29 minutes

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.0400+0.0200 (+1.96%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.0200
Open1.0200
Bid0.9760 x 1100
Ask1.0500 x 900
Day's range0.9654 - 1.0600
52-week range0.7310 - 9.4000
Volume107,440
Avg. volume194,427
Market cap94.226M
Beta (5Y monthly)0.43
PE ratio (TTM)N/A
EPS (TTM)-0.9010
Earnings date02 Dec 2022 - 06 Dec 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.93
  • GlobeNewswire

    Genetron Health Announces Receipt of Notification from Nasdaq

    BEIJING, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated October 28, 2022, indicating that fo

  • GlobeNewswire

    Genetron Health Reports Unaudited Second Quarter 2022 Financial Results

    BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory

  • GlobeNewswire

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the “Special Committee”) of the Company’s Board of Directors (the “Board”) has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice